

# HSCT Outcomes by Quarter: 2025 Transplant Cohort

## Quarterly Analysis of Transplant Events and Outcomes

### Transplant Outcomes Analysis

2026-01-21

#### Note

This report was generated using AI under general human direction. At the time of generation, the contents have not been comprehensively reviewed by a human analyst.

## Executive Summary

This report analyzes transplant outcomes for **26 patients** who underwent HSCT during calendar year 2025, broken down by quarter (trimester).

### Quarterly Distribution:

- **\*\*Q1 2025\*\*: 7 transplants**
- **\*\*Q2 2025\*\*: 4 transplants**
- **\*\*Q3 2025\*\*: 8 transplants**
- **\*\*Q4 2025\*\*: 7 transplants**

### Overall Results:

- **Total Deaths:** 1 (3.8%)
- **Overall Survival (all patients):** 96.2%

#### Limited Follow-up Period

This cohort has **limited follow-up time** with transplants occurring throughout 2025. Earlier quarters have longer follow-up, while Q4 2025 patients have minimal follow-up

time. Results should be interpreted with caution, especially for late timepoints (365 days).

## Overall Analysis by Quarter

### Cohort Characteristics by Quarter

Table 1: Cohort Characteristics by Quarter (2025)

Quarter	N Patients	Deaths	Median Age	M/F	CR	Not CR	Median F/U (days)
Q1 2025	7	0	59	2/5	5	2	312
Q2 2025	4	0	52	3/1	2	2	232
Q3 2025	8	0	60	2/6	8	0	152
Q4 2025	7	1	61	5/2	5	2	51

### Overall Survival by Quarter

#### Deaths and Survival at Key Timepoints

Table 2: Overall Survival at 30, 100, and 365 Days by Quarter

Quarter	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
Q1 2025	7	0	7/7 (100%)	0	7/7 (100%)	0	7/7 (100%)
Q2 2025	4	0	4/4 (100%)	0	4/4 (100%)	0	4/4 (100%)
Q3 2025	8	0	8/8 (100%)	0	8/8 (100%)	0	8/8 (100%)
Q4 2025	7	1	6/7 (85.7%)	1	6/7 (85.7%)	1	6/7 (85.7%)

## Analysis by Complete Remission Status

### Q1 2025: Complete Remission vs Not in CR

Table 3: Q1 2025: Overall Survival by Complete Remission Status

Disease Status	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
Complete Remission	5	0	5/5 (100%)	0	5/5 (100%)	0	5/5 (100%)
Not in Complete Remission	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)

### Q2 2025: Complete Remission vs Not in CR

Table 4: Q2 2025: Overall Survival by Complete Remission Status

Disease Status	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
Complete Remission	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
Not in Complete Remission	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)

### Q3 2025: Complete Remission vs Not in CR

Table 5: Q3 2025: Overall Survival by Complete Remission Status

Disease Status	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
Complete Remission	8	0	8/8 (100%)	0	8/8 (100%)	0	8/8 (100%)

### Q4 2025: Complete Remission vs Not in CR

Table 6: Q4 2025: Overall Survival by Complete Remission Status

Disease Status	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
Complete Remission	5	1	4/5 (80%)	1	4/5 (80%)	1	4/5 (80%)

Not in Complete Remission	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
---------------------------	---	---	------------	---	------------	---	------------

---

## Analysis by Donor Type

### Q1 2025: By Donor Type

Table 7: Q1 2025: Overall Survival by Donor Type

Donor Type	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
MUD	4	0	4/4 (100%)	0	4/4 (100%)	0	4/4 (100%)
MMUD	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
Haploididential	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)

### Q2 2025: By Donor Type

Table 8: Q2 2025: Overall Survival by Donor Type

Donor Type	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
MUD	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)
Sibling HLA-identical	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
Haploididential	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)

### Q3 2025: By Donor Type

Table 9: Q3 2025: Overall Survival by Donor Type

Donor Type	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
Haploididential	3	0	3/3 (100%)	0	3/3 (100%)	0	3/3 (100%)
MMUD	3	0	3/3 (100%)	0	3/3 (100%)	0	3/3 (100%)
MUD	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)

## **Q4 2025: By Donor Type**

Table 10: Q4 2025: Overall Survival by Donor Type

Donor Type	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
Haploidentical	3	1	2/3 (66.7%)	1	2/3 (66.7%)	1	2/3 (66.7%)
MMUD	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
MUD	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)

## **Analysis by Donor Type and Complete Remission Status**

### **Q1 2025: Donor Type (Complete Remission Only)**

Table 11: Q1 2025: Overall Survival by Donor Type (Complete Remission Only)

Donor Type	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
MUD	3	0	3/3 (100%)	0	3/3 (100%)	0	3/3 (100%)
MMUD	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)
Haploidentical	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)

### **Q1 2025: Donor Type (Not in Complete Remission Only)**

Table 12: Q1 2025: Overall Survival by Donor Type (Not in Complete Remission Only)

Donor Type	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
MUD	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)
MMUD	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)

### **Q2 2025: Donor Type (Complete Remission Only)**

Table 13: Q2 2025: Overall Survival by Donor Type (Complete Remission Only)

Donor Type	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
MUD	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)
Haploididential	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)

### Q2 2025: Donor Type (Not in Complete Remission Only)

Table 14: Q2 2025: Overall Survival by Donor Type (Not in Complete Remission Only)

Donor Type	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
Sibling HLA-identical	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)

### Q3 2025: Donor Type (Complete Remission Only)

Table 15: Q3 2025: Overall Survival by Donor Type (Complete Remission Only)

Donor Type	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
Haploididential	3	0	3/3 (100%)	0	3/3 (100%)	0	3/3 (100%)
MMUD	3	0	3/3 (100%)	0	3/3 (100%)	0	3/3 (100%)
MUD	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)

### Q3 2025: Donor Type (Not in Complete Remission Only)

No Not in CR patients in Q3 2025

### Q4 2025: Donor Type (Complete Remission Only)

Table 16: Q4 2025: Overall Survival by Donor Type (Complete Remission Only)

Donor Type	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)

Haploidentical	3	1	2/3 (66.7%)	1	2/3 (66.7%)	1	2/3 (66.7%)
MMUD	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)
MUD	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)

#### **Q4 2025: Donor Type (Not in Complete Remission Only)**

Table 17: Q4 2025: Overall Survival by Donor Type (Not in Complete Remission Only)

Donor Type	N	Day 30		Day 100		Day 365	
		Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
MUD	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)
MMUD	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)

## **Summary Tables**

### **All Quarters: Complete Remission Status**

Table 18: Overall Survival by Quarter and Complete Remission Status (All 2025)

Quarter	Disease Status	N	Day 30		Day 100		Day 365	
			Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
Q1 2025	Complete Remission	5	0	5/5 (100%)	0	5/5 (100%)	0	5/5 (100%)
Q1 2025	Not in Complete Remission	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
Q2 2025	Complete Remission	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
Q2 2025	Not in Complete Remission	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
Q3 2025	Complete Remission	8	0	8/8 (100%)	0	8/8 (100%)	0	8/8 (100%)
Q4 2025	Complete Remission	5	1	4/5 (80%)	1	4/5 (80%)	1	4/5 (80%)
Q4 2025	Not in Complete Remission	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)

### **All Quarters: Donor Type**

Table 19: Overall Survival by Quarter and Donor Type (All 2025)

	Day 30	Day 100	Day 365

Quarter	Donor Type	N	Deaths	OS (n/N %)	Deaths	OS (n/N %)	Deaths	OS (n/N %)
Q1 2025	MUD	4	0	4/4 (100%)	0	4/4 (100%)	0	4/4 (100%)
Q1 2025	MMUD	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
Q1 2025	Haploidentical	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)
Q2 2025	MUD	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)
Q2 2025	Sibling HLA-identical	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
Q2 2025	Haploidentical	1	0	1/1 (100%)	0	1/1 (100%)	0	1/1 (100%)
Q3 2025	Haploidentical	3	0	3/3 (100%)	0	3/3 (100%)	0	3/3 (100%)
Q3 2025	MMUD	3	0	3/3 (100%)	0	3/3 (100%)	0	3/3 (100%)
Q3 2025	MUD	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
Q4 2025	Haploidentical	3	1	2/3 (66.7%)	1	2/3 (66.7%)	1	2/3 (66.7%)
Q4 2025	MMUD	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)
Q4 2025	MUD	2	0	2/2 (100%)	0	2/2 (100%)	0	2/2 (100%)

### All Quarters: Donor Type Stratified by Complete Remission Status

Table 20: Overall Survival by Quarter, Donor Type, and Complete Remission Status (All)

Quarter	CR Status	Donor Type	N	Day 30		Day 100	
				Deaths	OS (n/N %)	Deaths	OS (n/N %)
Q1 2025	Complete Remission	MUD	3	0	3/3 (100%)	0	3/3 (100%)
Q1 2025	Complete Remission	MMUD	1	0	1/1 (100%)	0	1/1 (100%)
Q1 2025	Complete Remission	Haploidentical	1	0	1/1 (100%)	0	1/1 (100%)
Q1 2025	Not in Complete Remission	MUD	1	0	1/1 (100%)	0	1/1 (100%)
Q1 2025	Not in Complete Remission	MMUD	1	0	1/1 (100%)	0	1/1 (100%)
Q2 2025	Complete Remission	MUD	1	0	1/1 (100%)	0	1/1 (100%)
Q2 2025	Complete Remission	Haploidentical	1	0	1/1 (100%)	0	1/1 (100%)
Q2 2025	Not in Complete Remission	Sibling HLA-identical	2	0	2/2 (100%)	0	2/2 (100%)
Q3 2025	Complete Remission	Haploidentical	3	0	3/3 (100%)	0	3/3 (100%)
Q3 2025	Complete Remission	MMUD	3	0	3/3 (100%)	0	3/3 (100%)
Q3 2025	Complete Remission	MUD	2	0	2/2 (100%)	0	2/2 (100%)
Q4 2025	Complete Remission	Haploidentical	3	1	2/3 (66.7%)	1	2/3 (66.7%)
Q4 2025	Complete Remission	MMUD	1	0	1/1 (100%)	0	1/1 (100%)
Q4 2025	Complete Remission	MUD	1	0	1/1 (100%)	0	1/1 (100%)
Q4 2025	Not in Complete Remission	MUD	1	0	1/1 (100%)	0	1/1 (100%)
Q4 2025	Not in Complete Remission	MMUD	1	0	1/1 (100%)	0	1/1 (100%)

---

*Report generated on January 21, 2026*

*Analysis includes only patients transplanted in calendar year 2025, organized by quarter (trimester)*